Financials
Financial year 2024
FirstPharma from Hove, company number BE0597961547, closed financial year 2024 with a result of € -5,822 after tax. For that financial year FirstPharma recorded a gross margin of € 161 and equity of € 39,767. Compared with financial year 2023, the result moved from € 81,200 to € -5,822. The company made a loss. The company holds a healthy buffer. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on August 29, 2025.
€ 39,767
▼ 13% vs 2023
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -5,822
▼ still € 81,200 profit in 2023
Profit after tax over the fiscal year.
€ 38,216
▲ 62% vs 2023
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € 32,917.
Debts at end 2024
€ 8,452
Loans from banks and other lenders, long and short.
€ 157,021
▼ 29% vs 2023
Supplier invoices still open on the last day of the fiscal year.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2021 | 2022 | 2023 | 2024 | Change 2023 → 2024 | |
|---|---|---|---|---|---|
| Gross margin | € -116,324 | € 105,815 | € 95,749 | € 161 | ▼ € 95,588 |
| Profit after taxes | € -117,225 | € 97,217 | € 81,200 | € -5,822 | ▼ € 87,022 |
| Equity | € -132,827 | € -35,610 | € 45,590 | € 39,767 | ▼ 13% |
| Total debts | € 207,327 | € 509,043 | € 230,039 | € 165,473 | ▼ 28% |
| Cash | € 19,879 | € 110,496 | € 23,611 | € 38,216 | ▲ 62% |
| Retained profit | € -139,677 | € -42,460 | € 38,740 | € 32,917 | ▼ 15% |
| Bank debt | € 0 | € 0 | € 0 | € 8,452 | |
| Balance sheet total | € 74,500 | € 473,433 | € 275,629 | € 205,240 | ▼ 26% |
Key figures of FirstPharma, fiscal years 2021 to 2024, from the annual accounts filed with the National Bank of Belgium.The annual account for fiscal year 2025 has not been filed yet; it was expected before 31 July 2026.
What happened to FirstPharma?
What happened at FirstPharma in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2024: loss of € 5,822 (▼ € 87,022 vs 2023). filed late Source: NBB ↗
- New establishment in Hove. KBO
- Start of the company according to the CBE. KBO
- Alegria Comm. V. became a director. NBB
- Déjà Vu Comm. V. became a director. NBB
- Levante Comm V. became a director. NBB
- Salento Comm. V. became a director. NBB
In short
From € 117,225 loss in 2021 to € 5,822 loss in 2024.
Paid € 9,256 in corporate taxes since 2021.
Best year ever: 2022, with € 97,217 profit.
A new publication or filing at FirstPharma? We notify you, reason included.
Follow FirstPharmaDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind FirstPharma are Alegria Comm. V., Déjà Vu Comm. V., Levante Comm V. and Salento Comm. V.. The same people are also behind PENELOPE-ANTWERPEN, Apotheek Antverpia, BRONKHORST, ANIMMO and ANTWERPS DISTRIBUTIE CENTRUM.
Directors
According to the 2024 annual accounts
Director · represented by Geert Van Genechten
Also active at: PENELOPE-ANTWERPEN, Apotheek Antverpia, BRONKHORST, ANIMMO, ANTWERPS DISTRIBUTIE CENTRUM, FARMA DE BOND, VITAFARMA
since 2015
Director · represented by Koen Van Genechten
Also active at: PENELOPE-ANTWERPEN, Apotheek Antverpia, BRONKHORST, ANIMMO, ANTWERPS DISTRIBUTIE CENTRUM, FARMA DE BOND, VITAFARMA
since 2015
Director · represented by Hilde Van Genechten
Also active at: PENELOPE-ANTWERPEN, Apotheek Antverpia, BRONKHORST, ANIMMO, ANTWERPS DISTRIBUTIE CENTRUM, FARMA DE BOND, VITAFARMA
since 2015
Director · represented by Katleen Van Genechten
Also active at: PENELOPE-ANTWERPEN, Apotheek Antverpia, BRONKHORST, ANIMMO, ANTWERPS DISTRIBUTIE CENTRUM, FARMA DE BOND, VITAFARMA
since 2015
Establishments
Establishment units
Physical locations of this company
Boechoutsesteenweg 17
2540 Hove
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0597.961.547
- VAT number
- BE 0597.961.547
- Registered office
- Boechoutsesteenweg 17, 2540 Hove
- Names & denominations
- FirstPharma
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 13 February 2015
- Peppol
- Active · Active since 1 Jan 2001
- Activities · NACE
Handelsbemiddeling in de groothandel in voedings- en genotmiddelen
Overige niet-gespecialiseerde detailhandel
Overige detailhandel in voedingsmiddelen, neg
Detailhandel in cosmetica en toiletartikelen
Detailhandel via postorderbedrijven of via internet
Overige detailhandel in voedingsmiddelen in gespecialiseerde winkels, n.e.g.